Kanurra Makes Pharmacy Benefits Auditable by Design

Kanurra is building a pharmacy benefit manager for self-funded and level-funded employers that want to see where every prescription dollar goes. Founded in New York in 2026 by Semih Gultekin, the company says it charges one fixed administrative fee per employee, passes drug costs through without spread or markup, and credits every rebate dollar it receives back to the employer plan.

The pitch is not that pharmacy benefits need another dashboard. It is that the business model behind the dashboard should stop rewarding opacity. Kanurra is trying to make the claim itself the receipt, with acquisition cost, dispensing fee, rebate, and net plan cost visible at the fill level.

Kanurra matters now because employers are carrying a fiduciary burden that the traditional pharmacy-benefit stack often makes difficult to inspect. The company has fresh capital, an increasingly explicit product, and a market that has learned to ask harder questions about spread pricing, retained rebates, and pharmacy steering.

About Kanurra

Kanurra is a New York-based pharmacy benefit manager focused on small and midsize employers with self-funded or level-funded health plans. The company also sells through the brokers, benefits advisors, third-party administrators, and captive programs that help employers assemble and manage those plans.

Semih Gultekin founded Kanurra after working on clinical and agentic systems in healthcare. Kanurra's official biography says Gultekin previously served as CTO of a healthcare-AI company through its acquisition. That background matters because a PBM is not merely a pricing website. It is a mix of software, financial incentives, regulated workflows, employer data, pharmacy networks, clinical review, and implementation discipline.

Kanurra announced $6.5M in financing on September 29, 2026 from Necessary Ventures, Asylum Ventures, Daybreak Ventures, Virtue VC, Ford Street Ventures, and Browder Capital. An earlier founder disclosure described $6.35M from the same core investor group, so the public record contains a small amount discrepancy rather than evidence of a second round.

Why Kanurra's Incentive Design Matters

Kanurra's central product choice is also its central economic choice. The company says it earns one flat per-employee-per-month administrative fee that is fixed in the employer contract. Kanurra says it does not add spread to a prescription claim, retain manufacturer rebates as revenue, charge a percentage of drug spend, or profit more when the plan's pharmacy bill rises.

That structure is meant to make the PBM easier to audit. Under Kanurra's stated model, the employer pays what the pharmacy was paid for the drug, then sees rebates credited to the plan on the related claim. The separate administrative fee is the only revenue line. The elegance is not cosmetic. If the model works as described, the PBM's compensation is no longer hiding inside the number it is supposed to manage.

Kanurra's product also promises a claim-level ledger that exposes acquisition cost, dispensing fee, rebate, and net plan cost. The company offers to run a no-cost audit against an employer's existing claims before a switch. Those features turn transparency from a quarterly presentation into something closer to an operating control, although Kanurra has not published independent audits showing that its savings examples generalize across customers.

The PBM Market Is Asking for Receipts

The market problem is not theoretical. In a January 2025 staff report, the Federal Trade Commission said the Big 3 PBMs' affiliated pharmacies generated more than $7.3B in dispensing revenue above estimated acquisition cost on the specialty generic drugs it analyzed from 2017 through 2022. The FTC also estimated $1.4B in separate spread-pricing income on those drugs.

Those findings do not prove Kanurra's product will deliver lower costs. They do explain why employers, advisors, and regulators are increasingly unwilling to treat a prescription invoice as a sealed box. When the administrator earns money from the gap between what the pharmacy receives and what the plan pays, the customer is being asked to trust an incentive it cannot fully observe.

Kanurra is betting that smaller employers can demand a different arrangement without rebuilding the entire pharmacy network. The company says members can keep the pharmacies they already use, while Kanurra handles disruption analysis, eligibility files, ID cards, member communications, and continuity planning for open prior authorizations, specialty drugs, and GLP-1 therapies.

Clinical Controls and Operating Reality

Kanurra says its prior-authorization system uses automation to approve clean cases quickly but never lets AI deny a request. Anything outside the defined pathway is routed to a licensed clinician, and the company says a pharmacist owns the criteria and signs off on exceptions. That is a more credible boundary than promising fully automated clinical judgment, but it remains a company description rather than independently validated performance.

The company's corporate structure shows how much regulated work still sits behind the software. Kanurra Pharmacy LLC was organized in Idaho on September 17, 2026 as a wholly owned, non-dispensing subsidiary of Kanurra, Inc. Kanurra's September disclosure said the subsidiary's pharmacy license, NPI, and NCPDP Provider ID had not yet been issued and that the entity was not operating.

That disclosure is useful precisely because it is not polished away. The company is early. Kanurra has not publicly named customers, disclosed revenue or covered lives, published audited savings, or released independent validation of its prior-authorization workflow. The opportunity is visible, and so is the execution risk.

Leadership, Hiring, and the Build Ahead

Gultekin is the only current executive Kanurra identifies publicly through authoritative sources. The founder's earlier financing announcement said the company had its first customers ready to go and was seeing interest from brokers, TPAs, and captives, but those customers were not named and no operating metrics were disclosed.

Kanurra is hiring across clinical pharmacy, operations, sales and go-to-market, and engineering. There is no verified official careers page, so that hiring signal should be read as a map of the work ahead rather than a recruiting campaign. The company needs people who can make clinical policy defensible, implement benefits without member disruption, earn channel trust, and turn complex claim data into auditable infrastructure. The founder has directed interested candidates to semih@kanurra.com.

The mix of roles is the strategic signal. Kanurra is not only writing software. It is building a service operation that must survive plan-year deadlines, broker scrutiny, pharmacy-network dependencies, regulatory obligations, and real patients waiting at real counters.

What Kanurra Signals for Pharmacy Benefits

Kanurra represents a broader shift from negotiated opacity toward inspectable administration. Employers are being pushed to understand fees, conflicts, and outcomes with greater precision. A PBM designed around a fixed fee and claim-level reconciliation fits that direction because it gives the plan sponsor an answer that can be shown to a CFO, benefits committee, or board.

The difficult part begins after the model sounds obvious. Kanurra must prove it can implement groups cleanly, manage clinical exceptions, connect established industry rails, secure the licenses and identifiers its operating structure requires, and produce independently credible results. Transparency is the opening argument. Operational reliability will decide the case.

For founders and operators watching healthcare infrastructure, Kanurra is worth tracking because it attacks an old market with a narrow incentive reset. It is not promising to replace every component of the pharmacy system. It is trying to make the money visible, keep its own compensation separate, and force the service layer to show its work.